X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (100006) 100006
Newspaper Article (3159) 3159
Patent (2862) 2862
Newsletter (1389) 1389
Book Chapter (422) 422
Magazine Article (247) 247
Transcript (41) 41
Trade Publication Article (27) 27
Dissertation (25) 25
Book Review (20) 20
Government Document (17) 17
Publication (13) 13
Web Resource (13) 13
Conference Proceeding (12) 12
Reference (12) 12
Book / eBook (9) 9
Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (51914) 51914
humans (48143) 48143
male (40215) 40215
enzymes (32225) 32225
female (24208) 24208
rats (23794) 23794
mice (19048) 19048
enzyme inhibitors - pharmacology (18316) 18316
pharmacology & pharmacy (15905) 15905
proteins (12692) 12692
middle aged (11214) 11214
research (11172) 11172
adult (9998) 9998
expression (9869) 9869
enzyme-linked immunosorbent assay (9769) 9769
analysis (9331) 9331
neurosciences (9084) 9084
biochemistry & molecular biology (9066) 9066
apoptosis (8990) 8990
rodents (8846) 8846
dose-response relationship, drug (8797) 8797
rats, sprague-dawley (8635) 8635
oxidative stress (8541) 8541
metabolism (8453) 8453
physiological aspects (8342) 8342
aged (8339) 8339
oncology (8259) 8259
inflammation (8151) 8151
cell biology (8139) 8139
research article (7916) 7916
cancer (7629) 7629
health aspects (7590) 7590
medicine (7550) 7550
gene expression (7533) 7533
biochemistry (7459) 7459
disease models, animal (7146) 7146
physiology (7131) 7131
rats, wistar (6916) 6916
inhibition (6910) 6910
multidisciplinary sciences (6427) 6427
activation (6305) 6305
time factors (6289) 6289
care and treatment (6181) 6181
hypertension (6141) 6141
kinases (6096) 6096
nitric oxide (5903) 5903
studies (5767) 5767
enzyme inhibitors - administration & dosage (5394) 5394
cells, cultured (5361) 5361
enzyme inhibitors (5345) 5345
immunology (5308) 5308
chemistry (5263) 5263
science (5238) 5238
signal transduction (5220) 5220
angiotensin-converting enzyme inhibitors - therapeutic use (5175) 5175
phosphorylation (5136) 5136
enzyme inhibitors - therapeutic use (5066) 5066
microbiology (5063) 5063
cardiac & cardiovascular systems (5058) 5058
drug therapy (5051) 5051
mice, inbred c57bl (5030) 5030
treatment outcome (4955) 4955
cells (4918) 4918
blood pressure - drug effects (4768) 4768
medicine, research & experimental (4680) 4680
cytokines (4574) 4574
liver (4568) 4568
in-vitro (4499) 4499
brain (4456) 4456
cell line, tumor (4370) 4370
disease (4345) 4345
diabetes (4341) 4341
medicine & public health (4325) 4325
risk factors (4228) 4228
toxicology (4125) 4125
antioxidants (4123) 4123
peripheral vascular disease (4084) 4084
biology (4027) 4027
endocrinology & metabolism (4022) 4022
peptides (3929) 3929
enzyme activation - drug effects (3924) 3924
enzymology (3907) 3907
pharmacology (3891) 3891
genetic aspects (3885) 3885
apoptosis - drug effects (3876) 3876
administration, oral (3837) 3837
hypertension - drug therapy (3762) 3762
angiotensin-converting enzyme inhibitors - administration & dosage (3716) 3716
in-vivo (3670) 3670
pharmacokinetics (3632) 3632
mortality (3618) 3618
signal transduction - drug effects (3566) 3566
drug interactions (3562) 3562
blotting, western (3539) 3539
dosage and administration (3487) 3487
angiotensin (3434) 3434
medical research (3434) 3434
drugs (3424) 3424
drug therapy, combination (3401) 3401
nitric oxide synthase - antagonists & inhibitors (3380) 3380
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (106206) 106206
French (1665) 1665
Japanese (907) 907
German (759) 759
Russian (448) 448
Chinese (206) 206
Spanish (175) 175
Korean (83) 83
Polish (83) 83
Italian (78) 78
Portuguese (59) 59
Danish (56) 56
Hungarian (53) 53
Norwegian (40) 40
Swedish (38) 38
Ukrainian (26) 26
Czech (22) 22
Turkish (19) 19
Dutch (15) 15
Finnish (10) 10
Hebrew (8) 8
Lithuanian (8) 8
Slovak (8) 8
Bulgarian (7) 7
Croatian (6) 6
Romanian (6) 6
Arabic (4) 4
Serbian (4) 4
Slovenian (3) 3
Bosnian (2) 2
Greek (2) 2
Afrikaans (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 25, pp. 2562 - 2575
... Inhibitors in Renal Transplantation Henrik Ekberg, M.D., Ph.D., Helio Tedesco-Silva, M.D., Alper Demirbas, M.D., Štefan Vítko, M.D., Björn Nashan, M.D., Ph.D., Alp... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
...‐mg/day maintenance dose) and the proton‐pump inhibitor (PPI) omeprazole (80 mg) when they are administered simultaneously (study 1... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article
The American journal of medicine, ISSN 0002-9343, 2012, Volume 125, Issue 9, pp. 882 - 887.e1
...: aspirin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium-channel blockers, thiazides, and statins... 
Internal Medicine | Adherence | Prevention | Cardiovascular disease | PERSISTENCE | ACUTE CORONARY SYNDROMES | CONVERTING ENZYME-INHIBITORS | SECONDARY PREVENTION | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | STATIN THERAPY | ACUTE MYOCARDIAL-INFARCTION | BETA-BLOCKERS | MEDICATION ADHERENCE | ARTERY-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Medication Adherence - statistics & numerical data | Cardiovascular Agents - administration & dosage | Age Factors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Antihypertensive Agents - administration & dosage | Secondary Prevention - methods | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Aspirin - administration & dosage | Drug Prescriptions - statistics & numerical data | Self Administration | Time Factors | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Calcium Channel Blockers - administration & dosage | Primary Prevention - methods | Sodium Chloride Symporter Inhibitors - administration & dosage | Myocardial Infarction - prevention & control | Adrenergic beta-Antagonists - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Research | Patient compliance | Coronary heart disease | Drugs | Myocardial infarction | Aspirin | Side effects | Enzyme inhibitors | Risk reduction | Age | Statins
Journal Article
American journal of physiology. Cell physiology, ISSN 0363-6143, 03/2016, Volume 310, Issue 5, pp. C373 - C380
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 22, pp. 2071 - 2082
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2013, Volume 76, Issue 3, pp. 455 - 466
Aims The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Clinical pharmacology and therapeutics, ISSN 1532-6535, 2014, Volume 96, Issue 3, pp. 349 - 359
... (session 1), and with the CYP inhibitors fluvoxamine and voriconazole (session 2) and quinidine (session 3). In session 4, subjects received the cocktail after a 7... 
P4502B6 ACTIVITY | VORICONAZOLE | LC-MS/MS | SINGLE-POINT | ORAL MIDAZOLAM | VOLUNTEERS | IN-VIVO | PHARMACOLOGY & PHARMACY | DRUG-METABOLIZING-ENZYMES | KAROLINSKA COCKTAIL | BUPROPION HYDROXYLATION | Predictive Value of Tests | Pharmaceutical Preparations - blood | Caffeine - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Dried Blood Spot Testing | Humans | Omeprazole - blood | Bupropion - blood | Midazolam - administration & dosage | Substrate Specificity | Male | Chromatography, High Pressure Liquid | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Coffee | Terfenadine - administration & dosage | Caffeine - pharmacokinetics | Feasibility Studies | Enzyme Inhibitors - administration & dosage | Young Adult | Chromatography, Reverse-Phase | Tandem Mass Spectrometry | Capsules | Spectrometry, Mass, Electrospray Ionization | Flurbiprofen - administration & dosage | Adult | Dextromethorphan - pharmacokinetics | Terfenadine - blood | ATP-Binding Cassette, Sub-Family B, Member 1 - blood | Pharmaceutical Preparations - administration & dosage | Terfenadine - pharmacokinetics | Bupropion - pharmacokinetics | Flurbiprofen - pharmacokinetics | Cytochrome P-450 Enzyme System - blood | Administration, Oral | Isoenzymes | Caffeine - blood | Omeprazole - administration & dosage | Terfenadine - analogs & derivatives | Omeprazole - pharmacokinetics | Carbonated Beverages | Midazolam - pharmacokinetics | Bupropion - administration & dosage | Dextromethorphan - blood | Flurbiprofen - blood | Phenotype | Pilot Projects | Midazolam - blood | Dextromethorphan - administration & dosage | Usage | Glycoproteins | Liquid chromatography | Research | Pharmacokinetics | Cytochrome P-450 | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article